Anti-CD47 monoclonal antibody immunotherapy that blocks the CD47–SIRPα 'don't-eat-me' signal, enhancing macrophage-mediated phagocytosis of leukemia cells.
Anti-CD47 monoclonal antibody that blocks the CD47-SIRPa interaction, removing the 'don't eat me' signal and promoting macrophage-mediated phagocytosis of leukemia cells.
YES
DIRECT
Blocks CD47–SIRPα to remove the “don’t‑eat‑me” signal and engages Fcγ receptors on macrophages, inducing antibody‑dependent cellular phagocytosis (ADCP) of CD47+ cells.
Small-molecule BH3-mimetic BCL-2 inhibitor that triggers intrinsic (mitochondrial) apoptosis in AML cells.
Selective BH3-mimetic that inhibits BCL-2 by binding its hydrophobic groove, blocking its anti-apoptotic function and restoring intrinsic (mitochondrial) apoptosis in tumor cells; spares BCL-XL.
YES
DIRECT
Venetoclax directly inhibits BCL-2 as a BH3 mimetic, freeing BAX/BAK to induce mitochondrial outer membrane permeabilization, cytochrome c release, and caspase-mediated apoptosis in BCL-2–dependent cells.
Anti-HER2 antibody–drug conjugate that binds HER2 (effective in HER2-low), is internalized, and releases the MMAE payload to disrupt microtubules causing mitotic arrest and apoptosis; can also mediate ADCC and bystander killing.
Anti-HER2 antibody–drug conjugate that binds HER2 (effective in HER2-low), is internalized, and releases the MMAE payload to disrupt microtubules, causing mitotic arrest and apoptosis; can also mediate ADCC and bystander killing.
YES
DIRECT
The ADC binds HER2 on target cells, is internalized, and releases the MMAE payload, which disrupts microtubules causing mitotic arrest and apoptosis; Fc engagement can also trigger ADCC.
Anti-HER2 antibody–drug conjugate that binds HER2 (effective in HER2-low), is internalized, and releases the MMAE payload to disrupt microtubules causing mitotic arrest and apoptosis; can also mediate ADCC and bystander killing.
Anti-HER2 antibody–drug conjugate that binds HER2 (effective in HER2-low), is internalized, and releases the MMAE payload to disrupt microtubules, causing mitotic arrest and apoptosis; can also mediate ADCC and bystander killing.
NO
INDIRECT
RC48 binds HER2 (not beta-tubulin); after internalization it releases MMAE, which binds the vinca site on beta-tubulin to disrupt microtubules, causing mitotic arrest and apoptosis (with possible ADCC/bystander effects).
A FAP-targeted radiopharmaceutical: a 177Lu-labeled small-molecule FAPI ligand that selectively binds fibroblast activation protein on cancer-associated fibroblasts in the tumor stroma and delivers beta-emitting lutetium-177 to induce localized DNA double-strand breaks and cell death, with crossfire irradiation of adjacent tumor cells.
A 177Lu-labeled FAP inhibitor ligand that binds fibroblast activation protein on cancer-associated fibroblasts and delivers beta-emitting lutetium-177 to induce DNA double-strand breaks and cell death, with crossfire irradiation of adjacent tumor cells in the tumor microenvironment.
YES
DIRECT
The 177Lu-labeled FAP inhibitor binds FAP on cancer-associated fibroblasts; beta emissions from 177Lu induce DNA double-strand breaks in the FAP-expressing cells, killing them, with crossfire irradiation of nearby tumor cells.